The State of Emerging Biotechs: Investment, Deal, and Pipeline Trends

4:15 PM - 4:45 PM (PDT), Tuesday, June 14, 2022

David Thomas, BIO’s Vice President of Industry Analysis, will provide an overview of recent investment and deal trends for emerging therapeutic companies, as well as an update on the R&D pipeline and recent FDA approvals. The BIO Industry Analysis team publishes quarterly interactive data on licensing, M&A, venture capital, IPOs, follow-on public offerings, FDA approvals at In addition, details on the Covid Pipeline are published biweekly at Year-to-date updates will be presented during the session.